Chemotherapy versus chemo-BRM therapy in adenocarcinoma of the lung: In relation to quality of life
Yasutomo Nakai(Osaka International Cancer Institute), Masao Ôta(Shinshu University), Naohiko Ogawa, Junichi Saito, Keigo Kobayashi(Osaka Gakuin University), Kôichi Kimura, Sadahiro Koinumaru, M. Fukuoka, H Niitani, Yutaka Nishiwaki(National Cancer Center Hospital East), Akihiko Gemma(Nippon Medical School)
Cited by 0
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
|The Lancet Oncology|2019|642